Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe

Company Expands Market-leading Family of Neurovascular Stents

NATICK, Massachusetts, July 28, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced the
U.S. and European launches of the Neuroform EZ(TM) Stent System, its
fourth-generation intracranial aneurysm stent system designed for use in
conjunction with endovascular coiling to treat wide-necked aneurysms. The
Company plans to launch the product immediately in both markets.

The Neuroform EZ Stent System is engineered to provide
flexibility and conformability, especially in tortuous brain anatomy. It
employs Boston Scientific's proprietary Segmental(TM) Expansion technology,
designed to enhance stent anchoring and stability. The product features the
proven hybrid cell design of prior-generation Neuroform Stents while
incorporating a simplified, single-operator delivery system intended to
facilitate preparation, delivery and positioning of the stent.

The first Neuroform EZ Stent was implanted in the U.S. by
Demetrius Lopes, M.D., of the Rush University Medical Center in Chicago, and
the first European procedure was performed by Professor Laurent Spelle, M.D.,
Ph.D., at Foundation Rothschild Hospital, Beaujon School of Medicine in
Paris.

"The Neuroform EZ Stent System performed well in a very
challenging first procedure," said Dr. Lopes. "The smooth transfer of the
stent into the catheter, combined with excellent support, stability and
visibility, facilitated accurate stent placement."

"The improved delivery system of the Neuroform EZ Stent helped
me to place the stent exactly where I planned," said Professor Spelle. "In my
experience, Boston Scientific's new system is easier to use compared to its
previous microdelivery system and should offer benefits for both physicians
and patients."

"Boston Scientific is pleased to offer this new technology,
which is designed to help physicians simplify these complex neurovascular
procedures," said Mark Paul, President of Boston Scientific's Neurovascular
Division. "The Neuroform EZ Stent System reinforces our commitment to
providing advanced treatment options focused on improving patient care."

Boston Scientific will demonstrate its Neuroform EZ Stent
System at the 7th Annual Society of NeuroInterventional Surgery (SNIS)
Meeting, July 26 - 30 in Carlsbad, California.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
clinical trials, regulatory approvals, clinical outcomes and product
performance. If our underlying assumptions turn out to be incorrect, or if
certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have affected and
in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue reliance on
any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT:
    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

CONTACT: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation